Percutaneous Coronary Intervention

Long-term outcomes of PCI with a sirolimus-eluting stent vs. CABG for unprotected left main CAD.

A meta-analysis of 10 randomized trials demonstrated that the so-called “smoker’s paradox” of favorable short-term outcomes after primary PCI in STEMI may not exist after adjustment for other risk factors.

Myocardial flow reserve from PET imaging in patients with ischemic HF may identify those with a greater outcome benefit from CABG vs. PCI, according to data presented at the American College of Cardiology Scientific Session.

Patients with severely reduced left ventricular ejection fraction and CAD who underwent PCI had higher rates of MACE and mortality compared with those who underwent CABG, according to a study published in JAMA Cardiology.

In a pooled analysis of individual patient data from 21 trials, at 5 years after undergoing PCI, women had higher risk for MACE and ischemia-driven target lesion revascularization compared with men.

Among patients with ACS who underwent PCI with an ultrathin biodegradable polymer sirolimus-eluting stent, ticagrelor monotherapy after 3 months was superior at preventing net adverse clinical events compared with prolonged dual antiplatelet therapy with ticagrelor and aspirin, according to the results of the TICO trial.

Ten-year extended follow-up of the PRECOMBAT trial demonstrates no difference in the incidence of major adverse cardiac or cerebrovascular events regardless of whether patients with unprotected left main CAD were treated with PCI with a first-generation drug-eluting stent or CABG.

While not meeting a performance goal, genetic screening of patients with ACS or stable CAD after PCI to guide antiplatelet therapy choice numerically reduced serious adverse CV events, according to the results of the TAILOR PCI trial.

Among patients who underwent chronic total occlusion PCI, those with prior CABG had worse outcomes including higher rates of in-hospital morality, MI and coronary perforation compared with those without prior CABG, according to findings from a meta-analysis on the program at the American College of Cardiology Scientific Session.

Patients with chronic kidney disease who were assigned recombinant human C1 esterase inhibitor, or rhC1INH, before coronary angiography had a lower risk for renal injury compared with those assigned placebo, with a favorable safety profile, especially in those with multiple comorbidities, according to findings from the PROTECT study published in JACC: Cardiovascular Interventions.